NBA Fearless Forecast Weekly Rank: 19
NBA Fearless Forecast Weekly Rank: 19
Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a $50 million series A financing, to accelerate its innovative pipeline development and to support its unique conjugate technology platform. The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
The soap actor says her storyline took its toll on her life.
The "Future of User Interfaces Shaping New Consumer Experiences" report has been added to ResearchAndMarkets.com's offering.
A white board in the David Ellis Academy gymnasium is stuck on the wall. It details the planned activities for physical education classes on March 12, 2020 — the last day Ronda Brodsky taught physical education and health to students at the pre-K through eighth grade public charter school in Detroit. Like countless educators during the pandemic, Brodsky has had to make the adjustment to instructing her students virtually.
U.S. Vice President Kamala Harris is favourite to win the next presidential election with 22% implied probability, ahead of both Joe Biden and Donald Trump, according to betting odds from British bookmaker Ladbrokes. Harris is favourite to be next president, with 22.2% implied probability, while President Biden has 20% chance and former President Trump has 14.3% probability, Ladbrokes odds indicated.
Olivier Giroud was trusted to lead the line against United.
Teachers are not at a higher risk of infection in their jobs than people in other professions, data released by Britain's Office for National Statistics said on Monday, ahead of a planned reopening of schools in England next week. Prime Minister Boris Johnson has prioritised the reopening of schools as he plots a route out of England's third national lockdown. Britain's Office for National Statistics found no statistical evidence of a difference between school staff testing positive for coronavirus antibodies compared with the wider working-age population in the same local authorities.
STL (NSE: STLTECH), an industry-leading integrator of digital networks, today announced major new deals and extensions to current engagement with leading telcos in the Middle East and Africa region (MEA). The deals worth more than $100 million take STL's order book to a record high of ~Rs 11,300 Crores and exhibit the company's unwavering focus on building future-ready digital networks in the region.
The "Diaphragm Pump Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The "Food Traceability Market - A Global and Regional Study: Focus on Products (Barcode, RFID, Infrared), Applications (Dairy, Meat, Poultry and Seafood), End-User (Food Retailer, Food Manufacturer, Warehouses) and Country-Level Analysis - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
Ivy High Income Opportunities Fund Announces Monthly Distribution
A $300,000 donation from GFL Environmental Inc. ("GFL" or "GFL Environmental") is helping to make essential improvements to a local trauma centre's critical care facilities.
WEX announced today its agreement with OMV, expanding its presence within Europe.
TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Unigold Inc. (“Unigold” or the “Company”) (TSX-V:UGD; OTCQX: UGDIF; FSE:UGD1) is pleased to announce the appointment of Sr. Ramón Oscar Tapia Marion Landais as the Country Director in the Dominican Republic. Sr. Tapia will be responsible for supervising all activities of Unigold Inc., and it’s operating subsidiaries, in the Dominican Republic as Unigold moves towards development of its Candelones Project. Joseph Hamilton, Chairman and CEO of Unigold, comments, “I am excited to welcome Ramón into the senior management team at Unigold. We are fortunate to have been able to attract someone with Sr. Tapia’s skills, experience, and comprehensive knowledge of Dominican legislation to oversee the growth of Unigold in the Dominican Republic. Sr. Tapia will be instrumental in building our in-country administrative, technical, and public relations teams. We look forward to working with Ramón as we move through this transformative phase for Unigold.” Mr. Tapia is a resident of Santo Domingo in the Dominican Republic. He was previously a partner at Marat Legal, a leading natural resources law firm in Santo Domingo. Mr. Tapia holds a Law degree from PUCMM in Santo Domingo, a Master of Business Administration degree from Barna Management School, diplomas in Conflict Resolution and has been trained in International Commercial Arbitration. Mr. Tapia is a member of the Dominican Republic Bar Association and the Young Entrepreneurs Association of Dominican Republic. The Company also announces that the Board of Directors has approved the grant of stock options ("Options") to employees of the Company allowing for the acquisition of an aggregate of up to 1,000,000 common shares of the Company ("Shares") with an exercise price of $0.30 per Share and an expiry date of February 5, 2026. The options will vest at 25% every six months beginning August 5, 2021. The grant of Options were issued pursuant and subject to the terms and conditions of the Company's stock incentive plan and TSX Venture Exchange policies. About Unigold Inc. – Discovering Gold in the CaribbeanUnigold is a Canadian based mineral exploration company traded on the TSX Venture Exchange under the symbol UGD, focused primarily on exploring and developing its gold assets in the Dominican Republic. Forward-looking StatementsCertain statements contained in this document, including statements regarding events and financial trends that may affect our future operating results, financial position and cash flows, may constitute forward-looking statements within the meaning of the federal securities laws. These statements are based on our assumptions and estimates and are subject to risk and uncertainties. You can identify these forward-looking statements by the use of words like “strategy”, “expects”, “plans”, “believes”, “will”, “estimates”, “intends”, “projects”, “goals”, “targets”, and other words of similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts. We wish to caution you that such statements contained are just predictions or opinions and that actual events or results may differ materially. The forward-looking statements contained in this document are made as of the date hereof and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ materially from those projected in the forward-looking statements. Where applicable, we claim the protection of the safe harbour for forward-looking statements provided by the (United States) Private Securities Litigation Reform Act of 1995. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information please visit www.unigoldinc.com or contact: Mr. Joseph Hamilton Chairman & CEO email@example.com 416.866.8157
Top Players Covered in the disposable medical gloves market Research Report Are Kossan Rubber Industries Bhd (Selangor, Malaysia), Halyard Health (Georgia, United States), Ansell Ltd (Richmond, Australia), KANAM LATEX INDUSTRIES PVT LTD (Kerala, India), Top Glove Corporation Bhd (Shah Alam, Malaysia), Elite Surgical, Hartalega Holdings Bhd (Kuala Lumpur, Malaysia), Dynarex Corporation (New York, United States), Mölnlycke Health Care AB (Gothenburg, Sweden), Cardinal Health (Ohio, United States) and other key market players.Pune, India, March 01, 2021 (GLOBE NEWSWIRE) -- The global disposable medical gloves market is projected to gain impetus from the increasing awareness about health and safety, especially after the COVID-19 pandemic. Medical gloves or disposable gloves are used by medical practitioners during surgical or examining procedures. A recent report by Fortune Business Insights. The market will hit USD 14.03 billion by the end of 2027 from USD 5.95 billion in the year 2019. The forecast period is set between 2020 to 2027, and the market is expected to rise at a CAGR of 10.6%. Covid-19 Pandemic Propelling Personal Hygiene to Boost Market The increasing use of disposable gloves in the healthcare sector for personal health safety has propelled the medical gloves market. Additionally, the outbreak of several epidemics, especially the current COVID-19 pandemic and its emerging health threats has further increased the demand for disposable medical gloves from both the general public and healthcare professionals, thereby boosting the market growth. This, coupled with the increasing adoption of disposable gloves by various ends user industries such as beauty and skincare, food and beverage industry, and others will also add impetus to the market in the coming years. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/disposable-medical-gloves-market-101484 On the flip side, long term exposure to medical gloves may result in skin rashes, irritation, itchiness, and other skin issues, thereby hampering the market in the coming years. Nevertheless, increasing efforts by the players to launch user-friendly disposable gloves made of different materials are likely to create lucrative business opportunities for the market in the coming years. COVID-19 has a significant impact on both the healthcare sector and the world economy. Most of the industries are temporarily shut, and the ones that are operating from homes are barely trying to generate meagre income. We hope to soon overcome this difficult time with government support. Fortune Business Insights is offering special reports on various markets impacted by the COVID-19 pandemic. These reports provide insights into the current scenario of the specific markets so that key developers and investors can accordingly chalk out plans for better revenue generation in the years to come. Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/industry-reports/disposable-medical-gloves-market-101484 North America Held Largest Share Owing to Stringent Health Regulations Imposed by Government on Personal Health and Safety Geographically, North America earned USD 2.26 billion and emerged as the region with the highest disposable medical gloves market share in 2019, followed by Europe. This is attributable to the growing awareness about prevention of healthcare-related infections. The increasing demand for better quality polyisoprene medical gloves for surgical purpose is also adding a boost to the regional market growth. On the other side, Asia Pacific market will emerge as the fastest-growing region on account of the increasing adoption of nitrile gloves for medical examination procedures. This is further attributable to the decline in the cost of nitrile gloves and their puncture resistance features. Furthermore, the market in the Middle East and Africa is expected to rise significantly in the coming years on account of the rising medical awareness and expenditure on infrastructural development. Quick Buy - Disposable medical gloves market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101484 Some of the Key Players of this Market include: Kossan Rubber Industries Bhd (Selangor, Malaysia)Halyard Health (Georgia, United States)Ansell Ltd (Richmond, Australia)KANAM LATEX INDUSTRIES PVT LTD (Kerala, India)Top Glove Corporation Bhd (Shah Alam, Malaysia)Elite SurgicalHartalega Holdings Bhd (Kuala Lumpur, Malaysia)Dynarex Corporation (New York, United States)Mölnlycke Health Care AB (Gothenburg, Sweden)Cardinal Health (Ohio, United States)Others Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/disposable-medical-gloves-market-101484 Some major points from Table of Content: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1. Overview of Latex Allergy- Key Country/Region 4.2. 4.3. Healthcare Industry Overview-Key Country/Region- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, New Product Launches, etc.) 5. Global Disposable Medical Gloves Market Analysis, Insights and Forecast, 2016-2027 5.1. Key Findings / Summary 5.2. Market Analysis, Insights and Forecast – By Application 5.2.1. Surgical 5.2.2. Examination 5.3. Market Analysis, Insights and Forecast – By Material 5.3.1. Latex 5.3.2. Synthetic 184.108.40.206. Nitrile 220.127.116.11. Vinyl 18.104.22.168. Others 5.4. Market Analysis, Insights and Forecast – By Category 5.4.1. Powdered 5.4.2. Powder-free 5.5. Market Analysis, Insights and Forecast – By End-user 5.5.1. Hospitals & Clinics 5.5.2. Diagnostic/Pathology Labs 5.5.3. Dental Clinics 5.5.4. Others 5.6. Market Analysis, Insights and Forecast – By Region 5.6.1. North America 5.6.2. Europe 5.6.3. Asia Pacific 5.6.4. Latin America 5.6.5. Middle East & Africa 6. North America Disposable Medical Gloves Market Analysis, Insights and Forecast, 2016-2027 6.1. Key Findings / Summary 6.2. Market Analysis – By Application 6.2.1. Surgical 6.2.2. Examination 6.3. Market Analysis – By Material 6.3.1. Latex 6.3.2. Synthetic 22.214.171.124. Nitrile 126.96.36.199. Vinyl 188.8.131.52. Others 6.4. Market Analysis – By Category 6.4.1. Powdered 6.4.2. Powder-free 6.5. Market Analysis – By End-user 6.5.1. Hospitals & Clinics 6.5.2. Diagnostic/Pathology Labs 6.5.3. Dental Clinics 6.5.4. Others 6.6. Market Analysis – By Country 6.6.1. U.S. 6.6.2. Canada Continued... Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/disposable-medical-gloves-market-101484 Have a Look at Related Reports: Connected Drug Delivery Devices Market Size, Share & Industry Analysis, By Type (Injectable Devices and Inhalation Devices & Others) By Technology (Bluetooth, NFC, and Others) By End User (Homecare Settings and Hospitals) and Regional Forecast, 2019-2026 Hip Replacement Market Size, Share & Industry Analysis, By Procedure (Total Hip Replacement, Partial Hip Replacement, and Revision & Hip Resurfacing), By End User (Hospitals & Ambulatory Surgery Centers, Orthopedic Clinics, and Others) and Regional Forecast, 2019-2026 Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Material (Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, PMMA (Poly (methyl methacrylate)), Fat Fillers), By Product (Biodegradable and Non-biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement), By End User (Specialty & Dermatology Clinics, Hospital & Clinics), and Regional Forecast, 2020-2027 Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Material (Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, PMMA (Poly (methyl methacrylate)), Fat Fillers), By Product (Biodegradable and Non-biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement), By End User (Specialty & Dermatology Clinics, Hospital & Clinics), and Regional Forecast, 2020-2027 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: firstname.lastname@example.orgFortune Business Insights™LinkedIn | Twitter | Blogs Press Release: https://www.fortunebusinessinsights.com/press-release/disposable-medical-gloves-market-9283
The "Development of Leading IC Brands in Smart Vehicle Applications " report has been added to ResearchAndMarkets.com's offering.
EFECTE PLC -- COMPANY ANNOUNCEMENT -- 1 March 2021 at 13.45 Correction: Efecte Plc’s Notice of the Annual General Meeting 2021 This is a correction to the Efecte Plc’s Notice of the Annual General meeting 2021 published on 25 February 2021 at 8:30. Section C.5 of the English version of the Notice of the Annual General Meeting contained an error on the deadline for submitting questions pursuant to Chapter 5, Section 25 of the Limited Liability Companies Act. The English version of the notice incorrectly stated that the deadline is on 10 March 2021 at 10:00 (EET). The correct deadline is on 10 March 2021 at 16:00 (EET). The deadline is correctly stated in the Finnish version of the notice. Below is the corrected notice of the annual general meeting in full: Efecte Plc: Notice of the Annual General Meeting Notice is given to the shareholders of Efecte Plc to the Annual General Meeting to be held on Tuesday 23 March 2021 starting at 11:30 EET at the Company headquarters at the address Vaisalantie 6, Espoo, Finland. The Company’s shareholders may participate in the Annual General Meeting and exercise their shareholder rights only by voting in advance and by submitting counterproposals and asking questions in advance. Instructions for shareholders are provided in this notice’s section C. Instructions for the participants in the General Meeting. To prevent the spread of COVID-19 and to take into account the health and safety of the shareholders, employees and other stakeholders of the Company, the Board of Directors of the Company has resolved on exceptional meeting procedures based on the so-called temporary act (677/2020) which came into force on 3 October 2020. It is not possible to participate in the General Meeting in person at the meeting venue. If a shareholder wishes to submit questions to the Company’s management referred to in chapter 5, section 25 of the Limited Liability Companies Act, such questions need to be submitted in advance as further described below in section C.5, Other information, of this notice. The Company will publish the Chairman of the Board’s address and the review of the CEO as a video recording at the latest on Monday 8 March 2021, on the Company’s website at https://investors.efecte.com/en/annual-general-meeting-2021. Shareholders are requested to observe that the video recordings are not a part of the General Meeting or the official General Meeting material. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING At the Annual General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order Attorney-at-law Riikka Rannikko will serve as chairman of the meeting. In case Riikka Rannikko is prevented from serving as the chairman for a weighty reason, the Board of Directors will appoint the person they deem the most suitable to serve as the chairman. 3. Election of persons to scrutinise the minutes and to supervise the counting of votes The Company’s Legal Counsel Tatu Paavilainen will scrutinise the minutes and supervise the counting of votes. In the event Tatu Paavilainen is prevented from scrutinising the minutes and supervising the counting of votes for a weighty reason, the Board of Directors will appoint the person they deem the most suitable to scrutinise the minutes and supervise the counting of votes. 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and adoption of the list of votes Shareholders who have voted in advance within the advance voting period and who are entitled to participate in the General Meeting in accordance with Chapter 5, Sections 6 and 6 a of the Limited Liability Companies Act will be deemed shareholders participating in the meeting. The list of votes will be adopted according to the information provided by Euroclear Finland Oy and Innovatics Ltd. 6. Presentation of the Financial Statements, consolidated financial statements, the Report of the Board of Directors and the Auditor’s Report for the year 2020 As participation in the General Meeting is possible only by voting in advance, the annual review published by the Company on Thursday 25 February 2021, which includes the Company’s annual accounts, consolidated accounts, the report of the Board of Directors and the Auditor’s report is deemed to have been presented to the General Meeting. The annual review shall be available on the Company’s website no later than on the abovementioned date. 7. Adoption of the Financial Statements and the consolidated financial statements 8. Resolution on the use of the profit shown on the balance sheet and the payment of dividend The Board of Directors proposes to the Annual General Meeting that no dividend be distributed for the financial year that ended on 31 December 2020. 9. Resolution on the discharge of the members of the Board of Directors and the CEO from liability 10. Resolution on the remuneration of the members of the Board of Directors Efecte Plc’s shareholders who in total represent approximately 36 % of all of Efecte Plc’s shares and votes have proposed that the remuneration for the Chairman of the Board will be increased by EUR 333 per month and the remuneration for other members of the Board of Directors by EUR 250 per month. It has been proposed that the members be paid the following remuneration for their term of office: Chairman of the Board EUR 3,423 per month and the other members of the Board of Directors EUR 1,795 per month each. In addition, the above-mentioned shareholders propose that approximately 40 per cent of the remuneration be paid in Efecte Plc’s shares and approximately 60 per cent be paid in cash. The part of the remuneration paid in shares will be paid by issuing new shares and/or transferring company’s own shares to the Board members within four weeks from the release of the business review for 1 January - 31 March 2021 or, if this is not possible taking insider rules into account, as soon as possible thereafter. A member of the Board of Directors is not entitled to sell or transfer the shares received as Board remuneration during three years following the payment of the remuneration. In addition, the Chairman of the Board and the other members of the Board of Directors be compensated for reasonable travelling costs for attending the Board meetings. 11. Resolution on the number of members of the Board of Directors The Board of Directors proposes to the Annual General Meeting that six (6) members be elected to the Board. 12. Election of members of the Board of Directors Efecte Plc’s shareholders who in total represent approximately 36 % of all of Efecte Plc’s shares and votes have proposed that the current members of the Board Pertti Ervi, Turkka Keskinen, Kari J. Mäkelä, Päivi Rekonen, Brigitte Falk and Esther Donatz be re-elected to the Board for the term until the close of the next Annual General Meeting. 13. Resolution on the remuneration of the auditor The Board of Directors proposes to the Annual General Meeting that the remuneration of the auditor be paid against an invoice approved by the company. 14. Election of auditor The Board of Directors proposes to the Annual General Meeting that Ernst & Young Oy, a firm of authorised public accountants, be re-elected as the company’s auditor for the term until the close of the next Annual General Meeting. Ernst & Young Oy has notified the company that Authorised Public Accountant Juha Hilmola would be the company’s responsible auditor. 15. Authorising the Board to decide on the repurchase of the company’s own shares The Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to resolve to repurchase a maximum of 450,000 shares of the company in one or several instalments by using funds in the unrestricted shareholders’ equity. The proposed number of shares corresponds to approximately 7.4 per cent of all shares in the company. The shares may be repurchased in order to improve the capital structure of the company, to carry out acquisitions or other arrangements related to the company’s business, to be transferred or cancelled for other purposes, to be used in the company’s incentive plans, or if the Board of Directors otherwise deems it to be in the interest of shareholders. The price paid for the shares repurchased under the authorisation shall be based on the market price of the company’s share in public trading. The minimum price to be paid shall be the lowest market price of the share quoted in public trading during the authorisation period and the maximum price the highest market price quoted during the authorisation period. The company’s own shares may be repurchased otherwise than in proportion to the shareholdings of the shareholders (directed repurchase). It is proposed that the authorisation be effective until the next Annual General Meeting, however, at the latest until 30 June 2022. The authorisation will revoke the repurchase authorisation granted by the Annual General Meeting on 22 April 2020. 16. Authorising the Board to decide on the issuance of shares, option rights and other special rights entitling to shares The Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to decide on the issuance of shares, option rights and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Companies Act in one or several instalments in the manner described below. The Board would, pursuant to the authorisation, be entitled to decide on the issuance of an aggregate maximum of 608,000 new shares. The Board may decide to issue new shares or shares held by the company. The maximum number of shares included in the proposed authorisation accounts for approximately 10 per cent of the company’s shares. The authorisation includes the right to issue shares, option rights and/or other special rights entitling to shares through private offering, in other words, to deviate from the shareholders’ pre-emptive right, if there is a weighty financial reason for doing so from the company’s point of view, such as using them as consideration to carry out acquisitions or other arrangements or investments related to the company’s business, and/or as part of the remuneration of the Board members paid in shares as resolved by the Annual General Meeting. The authorisation also includes the right to issue shares, option rights and/or other special rights entitling to shares against payment or without charge. Issuance without charge requires that there is an especially weighty financial reason for doing so from the company’s point of view and taking the interests of the company’s all shareholders into consideration. Under the authorisation, the Board of Directors will be entitled to decide on any terms and conditions of the issuance of shares, option rights and other special rights entitling to shares, including the recipients and the compensation to be paid. It is proposed that the authorisation be effective until the next Annual General Meeting, however, at the latest until 30 June 2022. The authorisation will revoke the share issue authorisations granted by the Annual General Meeting on 22 April 2020. 17. Closing of the meeting B. DOCUMENTS OF THE ANNUAL GENERAL MEETING The above-mentioned proposals for decisions relating to the agenda of the Annual General Meeting as well as this notice are available on Efecte Plc’s website at https://investors.efecte.com/en/annual-general-meeting-2021. The Financial Statements, consolidated financial statements, the Report of the Board of Directors, and the Auditor’s Report of Efecte Plc will be available on the above-mentioned website on Thursday 25 February 2021. The proposals for decisions and other above-mentioned documents are also available at the Annual General Meeting. Copies of these documents and of this notice will be sent to shareholders upon request. The minutes of the meeting will be available on the above-mentioned website as of Tuesday 6 April 2021 at the latest. C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING In order to prevent the spread of the COVID-19 pandemic, the General Meeting will be organised so that the shareholder or the shareholder’s proxy representative is not allowed to participate in the General Meeting at the meeting venue. The Company’s shareholder can participate in the General Meeting and exercise the shareholder rights only in advance in accordance with the instructions set out below. 1. Shareholders registered in the shareholders’ register Each shareholder who on the record date of the Annual General Meeting, i.e. 11 March 2021, is registered in the shareholders’ register of the company held by Euroclear Finland Ltd has the right to participate in the Annual General Meeting. A shareholder whose shares are registered on his/her personal Finnish book-entry account is registered in the shareholders’ register of the company. The shareholder can participate in the General Meeting only by voting in advance and by submitting counterproposals and asking questions in advance as described below. 2. Notification of participation and voting in advance Notification of participation may be submitted, and advance voting will begin at 12 noon (EET) on Monday 8 March 2021. A shareholder who wishes to participate in the General Meeting by voting in advance must register for the General Meeting and vote in advance no later than by Tuesday 16 March 2021 at 4:00 pm (EET), by which time the notice of participation and advance votes must be received. The requested information, such as the shareholder’s name, personal identification number and contact details, must be provided in connection with the registration. The personal data given to Efecte Plc or Innovatics Ltd by shareholders will be used only in connection with the General Meeting, and with the processing of related registrations. A shareholder whose shares are registered on the shareholder’s Finnish book-entry account can submit the notice of participation and vote in advance on certain matters on the agenda of the General Meeting between 12 noon (EET) on 8 March 2021 and 4:00 pm (EET) on 16 March 2021 in the following ways: a) Through the Company’s website https://investors.efecte.com/en/annual-general-meeting-2021 Registering and voting in advance requires strong electronic identification (bank codes or the Mobile ID) for natural persons and business ID and the shareholder’s book-entry account number for legal persons. b) By mail or email A shareholder voting in advance by mail or email must send the advance voting form available on the Company’s website https://investors.efecte.com/en/annual-general-meeting-2021 or corresponding information to Innovatics Ltd by mail to the address Innovatics Ltd, General Meeting/Efecte Oyj, Ratamestarinkatu 13 A, 00520 Helsinki or by email to the address email@example.com. If the shareholder participates in the meeting by sending the votes in advance by mail or email to Innovatics Ltd so that they are received before the end of the time limit of the registration and advance voting period, this constitutes registration for the General Meeting, provided that the shareholder’s notice of participation includes the information required for registration mentioned on the advance voting form. The voting instructions will be available on the Company’s website at the address https://investors.efecte.com/en/annual-general-meeting-2021. Additional information is also available by telephone at +358 10 2818 909 during the time reserved for the notice of participation between 9:00 a.m. and 12:00 noon (EET) and 1:00 and 4:00 p.m. (EET) on weekdays. 3. Proxy representative and powers of attorney A shareholder may participate in the General Meeting and exercise the shareholder rights at the meeting by way of proxy representation. Shareholders’ proxy representatives must also vote in advance as set out in this notice. The proxy representative must personally identify themselves in the electronic identification service and for advance voting using strong identification, after which the proxy representative can register and vote in advance on behalf of the shareholder the proxy representative represents. The proxy representative shall produce a dated proxy document or otherwise in a reliable manner demonstrate their right to represent the shareholder at the General Meeting. A statutory representation right can be demonstrated by utilising the suomi.fi e-Authorisations service used in the electronic registration service. When a shareholder participates in the Annual General Meeting by means of several proxy representatives who represent the shareholder with shares on different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration. Proxy and voting instruction templates are available on the Company’s website at https://investors.efecte.com/en/annual-general-meeting-2021 at the latest on Monday 8 March 2021 at 12 noon (EET). Proxy documents are to be delivered primarily as an attachment in connection with the electronic registration, by email to the address firstname.lastname@example.org or by mail to the address Innovatics Ltd, General Meeting/Efecte Oyj, Ratamestarinkatu 13 A, 00520 Helsinki before the end of the notification of participation period, by which time the proxy documents must be received. Efecte Plc may, in its discretion, demand original proxy documents if regarded necessary by the Company. Submitting a proxy to Innovatics Ltd before the end of the notification of participation period constitutes due registration for the General Meeting, provided that the required information for the participation listed in this notice is given. A holder of nominee registered shares is advised to follow the instructions of such holder’s custodian bank regarding proxies as described in section 4. Holder of nominee registered shares below. If a holder of nominee registered shares wishes to be represented by some other person than such holder’s custodian, the representative must provide Innovatics Ltd a dated proxy demonstrating the right to represent the shareholder. 4. Holders of nominee-registered shares A holder of nominee registered shares has the right to participate in the General Meeting by virtue of such shares, based on which he/she would be entitled, on the record date of the Annual General Meeting, Thursday 11 March 2021, to be registered in the shareholders’ register of the company held by Euroclear Finland Ltd. In addition, the right to participate in the Annual General Meeting requires that the shareholder has, on the basis of such shares, been temporarily registered in the shareholders’ register held by Euroclear Finland Ltd at the latest by 18 March 2021 at 10:00 a.m. (EET). As regards nominee registered shares, this constitutes due registration for the General Meeting. Holders of nominee-registered shares are advised to request without delay necessary instructions regarding the temporary registration in the shareholders’ register of the company, the issuing of proxy documents, and preregistration for the Annual General Meeting from their custodian bank. The account manager of the custodian bank shall register a holder of nominee-registered shares who wishes to participate in the Annual General Meeting temporarily in the shareholders’ register of the company by the deadline stated above. The account management organisation of the custodian bank shall also arrange advance voting on behalf of the holder of nominee-registered shares during the registration period applicable to holders of nominee-registered shares. 5. Other information Shareholders who hold at least one-hundredth of all the shares in the Company have the right to make counterproposals on the matters on the agenda of the General Meeting to be put up for a vote. Such counterproposals must be sent to the Company by email to email@example.com no later than on Friday, 5 March 2021 at 12 noon (EET). In connection with making a counterproposal, shareholders are required to provide adequate evidence of their shareholding. The counterproposal will be put up for a vote in the General Meeting subject to the shareholder having the right to participate in the General Meeting and holding at least one-hundredth of all shares in the Company on the record date of the General Meeting, 11 March 2021. Should the counterproposal not be put up for a vote at the General Meeting, advance votes in favour of the proposal will not be taken into account. The Company will at the latest on Monday 8 March 2021 at 12 noon (EET) publish any counterproposals that may be voted on, on its website at the address https://investors.efecte.com/en/annual-general-meeting-2021. Shareholders have the right to ask questions and request information with respect to the matters to be considered at the meeting pursuant to Chapter 5, Section 25 of the Limited Liability Companies Act. Such questions can be made either in the online registration service or they can be sent by email to the address firstname.lastname@example.org or by mail to address Efecte Oyj / AGM, Vaisalantie 6, FI-02130 Espoo, Finland no later than at 16:00 (EET) on Wednesday 10 March 2021, by which time the questions must be received. The company will publish the shareholders’ questions along with the management’s responses as well as any counterproposals not eligible for voting on the company’s website https://investors.efecte.com/en/annual-general-meeting-2021 on Friday 12 March 2021 at the latest. Asking questions and making counterproposals requires the shareholder to present an adequate statement of their shareholding in the company. On the date of this notice to the Annual General Meeting, 25 February 2021, the total number of shares in Efecte Plc is 6,085,123 and the total number of votes in Efecte Plc is 6,085,123. Espoo, 25 February 2021 EFECTE PLC The Board of Directors Further inquiries: Tatu PaavilainenHead of Investor RelationsEfecte Plctatu.email@example.com+358 400 383 064 Taru MäkinenCFOEfecte Plctaru.firstname.lastname@example.org+358 40 507 1085 Certified Adviser:Evli Bank Plc, tel +358 40 579 6210 Efecte Plc Efecte helps service organizations digitalize and automate their work. Customers across Europe leverage our cloud service to operate with greater agility, to improve the experience of end-users, and to save costs. The use cases for our solutions range from IT service management and ticketing to improving employee experiences, business workflows, and customer service. We are the European Alternative to global players in our space. Our headquarters is located in Finland and we have regional hubs in Germany and Sweden. Efecte is listed on the Nasdaq First North Growth Market Finland marketplace. www.efecte.com
Piedmont Lithium Limited, ("Piedmont" or the "Company") (ASX: PLL; Nasdaq: PLL), a pre-production business targeting the integrated production of battery quality lithium hydroxide to support a US and global electric vehicle supply chain, today announced participation in several virtual conferences consisting of small group meetings, fireside chats, and panel discussions:
U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, today announced a newly expanded data agreement with leading global marketing and corporate communications company Omnicom Group Inc. (NYSE: OMC). Under the terms of the agreement, Comscore will provide privacy-safe e-commerce and audience behavioral data to Omni, the marketing operating system that supports Omnicom's global network of agencies. Omni identifies and defines personalized consumer experiences at scale, enabling more relevant and effective creative development, media planning/buying/optimization and analytics capabilities for Omnicom clients.